Primary Focal Segmental Glomerulosclerosis Clinical Trial
Official title:
A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS)
This is a multicenter, open label, randomized study investigating two dose titration regimens
of CXA-10 in subjects at least 18 years of age with primary FSGS.
The study will be performed at approximately 25 study centers across the United States of
America (USA). The recruitment period is anticipated to be up to approximately 16 months.
Approximately 30 subjects will be randomized to ensure 26 subjects complete the study. An
optional 9 month open label is available
This is a multicenter, open label, randomized study investigating two dose titration regimens
of CXA-10 in subjects at least 18 years of age with primary FSGS.
The study will be performed at approximately 25 study centers across the United States of
America (USA). The recruitment period is anticipated to be up to approximately 16 months.
Approximately 30 subjects will be randomized.
Study participation for each subject will last up to 5 months. The study will consist of a
screening period not to exceed 30 days (1 month), 90-day (3 month) treatment period, and an
approximate 28-day (1 month) follow-up period after the last dose of study medication. An
optional 9 month open label is available.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01573533 -
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
|
Phase 2 | |
| Active, not recruiting |
NCT04983888 -
Obinutuzumab in Primary FSGS
|
Phase 2 | |
| Not yet recruiting |
NCT06466135 -
Study of WAL0921 in Patients With Glomerular Kidney Diseases
|
Phase 2 | |
| Completed |
NCT01665391 -
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
|
Phase 2 | |
| Not yet recruiting |
NCT06315504 -
Circulating Factors in Nephrotic Syndrome
|